Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H31NO2.ClH |
Molecular Weight | 389.959 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=UXBPQRGCVJOTNT-COBSGTNCSA-N
InChI=1S/C23H31NO2.ClH/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21;/h7-16,18,22H,6,17H2,1-5H3;1H/t18-,22-;/m0./s1
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
139 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DINORACETYLMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
184 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NORACYMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
188 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LEVOMETHADYL ACETATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5892 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DINORACETYLMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6056 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NORACYMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2995 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LEVOMETHADYL ACETATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mg/kg multiple, oral Studied dose Dose: 3 mg/kg Route: oral Route: multiple Dose: 3 mg/kg Sources: |
unhealthy, 23 - 57 years n = 6 Health Status: unhealthy Condition: heroin dependency Age Group: 23 - 57 years Sex: M+F Population Size: 6 Sources: |
Disc. AE: Cardiotoxicity... AEs leading to discontinuation/dose reduction: Cardiotoxicity (6 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiotoxicity | 6 patients Disc. AE |
3 mg/kg multiple, oral Studied dose Dose: 3 mg/kg Route: oral Route: multiple Dose: 3 mg/kg Sources: |
unhealthy, 23 - 57 years n = 6 Health Status: unhealthy Condition: heroin dependency Age Group: 23 - 57 years Sex: M+F Population Size: 6 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
yes | likely (co-administration study) Comment: the addition of drugs that induce this enzyme (such as rifampin, phenobarbital, and phenytoin) or inhibit this enzyme (such as ketoconazole, erythromycin, and saquinavir) could increase the levels of parent drug or its active metabolites in a patient that was previously at steady-state, and this could potentially precipitate serious arrhythmias, including torsade de pointes |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
||
|
FDA ORPHAN DRUG |
4784
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
43033-72-3
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
Levomethadyl acetate hydrochloride
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
DBSALT001444
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
100000089116
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL1514
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
82043
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
C47583
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
6441
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
GG-23
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
m6789
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
B54CW5KG52
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
DTXSID7020500
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
39371
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY | |||
|
SUB14353MIG
Created by
admin on Fri Dec 15 15:14:21 GMT 2023 , Edited by admin on Fri Dec 15 15:14:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD